Effect of smoking status on clinical outcome and efficacy of clopidogrel in acute coronary syndrome

Masaki Kodaira, Hiroaki Miyata, Yohei Numasawa, Ikuko Ueda, Yuichiro Maekawa, Koichiro Sueyoshi, Shiro Ishikawa, Takahiro Ohki, Kouji Negishi, Keiichi Fukuda, Shun Kosaka

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: The “smoker’s paradox” is an otherwise unexplained phenomenon in which the mortality of smokers after acute myocardial infarction is reduced, contrary to expectations. It has been suggested that an association with antiplatelet agents exists, but the true mechanism remains largely unidentified. Methods and Results: The analysis included 6,195 consecutive patients who underwent percutaneous coronary intervention (PCI) for acute coronary syndrome, registered in the Japanese multicenter PCI registry. Smokers were significantly younger and had less comorbidity than non-smokers. Unadjusted in-hospital mortality rate, general complication rate, and bleeding complication rate were lower in smokers than in non-smokers. After adjustment, the trend persisted and smoking was not associated with overall mortality (odds ratio [OR], 0.90; 95% confidence interval [CI]: 0.61–1.34; P=0.62), and was associated with lower overall (P=0.032) and bleeding complication events (P=0.040). Clopidogrel effectively reduced the occurrence of in-hospital complications and major adverse cardiac events in smokers compared with non-smokers (OR, 0.55; 95% CI: 0.53–0.98 vs. OR, 1.20; 95% CI: 0.87–1.67; and OR, 0.37; 95% CI: 0.20–0.70 vs. OR, 1.48; 95% CI: 0.90–2.43, respectively). Conclusions: The smoker’s paradox was largely explained by confounding factors related to the lower risk profile of smokers, and they benefited from a positive modification of the efficacy of clopidogrel.

Original languageEnglish
Pages (from-to)1590-1599
Number of pages10
JournalCirculation Journal
Volume80
Issue number7
DOIs
Publication statusPublished - 2016

Fingerprint

clopidogrel
Acute Coronary Syndrome
Smoking
Odds Ratio
Confidence Intervals
Percutaneous Coronary Intervention
Mortality
Hemorrhage
Social Adjustment
Platelet Aggregation Inhibitors
Hospital Mortality
Registries
Comorbidity
Myocardial Infarction

Keywords

  • Acute coronary syndrome
  • Clopidogrel
  • Percutaneous coronary intervention
  • Smoking
  • ST-segment elevation myocardial infarction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effect of smoking status on clinical outcome and efficacy of clopidogrel in acute coronary syndrome. / Kodaira, Masaki; Miyata, Hiroaki; Numasawa, Yohei; Ueda, Ikuko; Maekawa, Yuichiro; Sueyoshi, Koichiro; Ishikawa, Shiro; Ohki, Takahiro; Negishi, Kouji; Fukuda, Keiichi; Kosaka, Shun.

In: Circulation Journal, Vol. 80, No. 7, 2016, p. 1590-1599.

Research output: Contribution to journalArticle

Kodaira, M, Miyata, H, Numasawa, Y, Ueda, I, Maekawa, Y, Sueyoshi, K, Ishikawa, S, Ohki, T, Negishi, K, Fukuda, K & Kosaka, S 2016, 'Effect of smoking status on clinical outcome and efficacy of clopidogrel in acute coronary syndrome', Circulation Journal, vol. 80, no. 7, pp. 1590-1599. https://doi.org/10.1253/circj.CJ-16-0032
Kodaira, Masaki ; Miyata, Hiroaki ; Numasawa, Yohei ; Ueda, Ikuko ; Maekawa, Yuichiro ; Sueyoshi, Koichiro ; Ishikawa, Shiro ; Ohki, Takahiro ; Negishi, Kouji ; Fukuda, Keiichi ; Kosaka, Shun. / Effect of smoking status on clinical outcome and efficacy of clopidogrel in acute coronary syndrome. In: Circulation Journal. 2016 ; Vol. 80, No. 7. pp. 1590-1599.
@article{aa43c2123c2e4af88df2b3b6abc63b86,
title = "Effect of smoking status on clinical outcome and efficacy of clopidogrel in acute coronary syndrome",
abstract = "Background: The “smoker’s paradox” is an otherwise unexplained phenomenon in which the mortality of smokers after acute myocardial infarction is reduced, contrary to expectations. It has been suggested that an association with antiplatelet agents exists, but the true mechanism remains largely unidentified. Methods and Results: The analysis included 6,195 consecutive patients who underwent percutaneous coronary intervention (PCI) for acute coronary syndrome, registered in the Japanese multicenter PCI registry. Smokers were significantly younger and had less comorbidity than non-smokers. Unadjusted in-hospital mortality rate, general complication rate, and bleeding complication rate were lower in smokers than in non-smokers. After adjustment, the trend persisted and smoking was not associated with overall mortality (odds ratio [OR], 0.90; 95{\%} confidence interval [CI]: 0.61–1.34; P=0.62), and was associated with lower overall (P=0.032) and bleeding complication events (P=0.040). Clopidogrel effectively reduced the occurrence of in-hospital complications and major adverse cardiac events in smokers compared with non-smokers (OR, 0.55; 95{\%} CI: 0.53–0.98 vs. OR, 1.20; 95{\%} CI: 0.87–1.67; and OR, 0.37; 95{\%} CI: 0.20–0.70 vs. OR, 1.48; 95{\%} CI: 0.90–2.43, respectively). Conclusions: The smoker’s paradox was largely explained by confounding factors related to the lower risk profile of smokers, and they benefited from a positive modification of the efficacy of clopidogrel.",
keywords = "Acute coronary syndrome, Clopidogrel, Percutaneous coronary intervention, Smoking, ST-segment elevation myocardial infarction",
author = "Masaki Kodaira and Hiroaki Miyata and Yohei Numasawa and Ikuko Ueda and Yuichiro Maekawa and Koichiro Sueyoshi and Shiro Ishikawa and Takahiro Ohki and Kouji Negishi and Keiichi Fukuda and Shun Kosaka",
year = "2016",
doi = "10.1253/circj.CJ-16-0032",
language = "English",
volume = "80",
pages = "1590--1599",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "7",

}

TY - JOUR

T1 - Effect of smoking status on clinical outcome and efficacy of clopidogrel in acute coronary syndrome

AU - Kodaira, Masaki

AU - Miyata, Hiroaki

AU - Numasawa, Yohei

AU - Ueda, Ikuko

AU - Maekawa, Yuichiro

AU - Sueyoshi, Koichiro

AU - Ishikawa, Shiro

AU - Ohki, Takahiro

AU - Negishi, Kouji

AU - Fukuda, Keiichi

AU - Kosaka, Shun

PY - 2016

Y1 - 2016

N2 - Background: The “smoker’s paradox” is an otherwise unexplained phenomenon in which the mortality of smokers after acute myocardial infarction is reduced, contrary to expectations. It has been suggested that an association with antiplatelet agents exists, but the true mechanism remains largely unidentified. Methods and Results: The analysis included 6,195 consecutive patients who underwent percutaneous coronary intervention (PCI) for acute coronary syndrome, registered in the Japanese multicenter PCI registry. Smokers were significantly younger and had less comorbidity than non-smokers. Unadjusted in-hospital mortality rate, general complication rate, and bleeding complication rate were lower in smokers than in non-smokers. After adjustment, the trend persisted and smoking was not associated with overall mortality (odds ratio [OR], 0.90; 95% confidence interval [CI]: 0.61–1.34; P=0.62), and was associated with lower overall (P=0.032) and bleeding complication events (P=0.040). Clopidogrel effectively reduced the occurrence of in-hospital complications and major adverse cardiac events in smokers compared with non-smokers (OR, 0.55; 95% CI: 0.53–0.98 vs. OR, 1.20; 95% CI: 0.87–1.67; and OR, 0.37; 95% CI: 0.20–0.70 vs. OR, 1.48; 95% CI: 0.90–2.43, respectively). Conclusions: The smoker’s paradox was largely explained by confounding factors related to the lower risk profile of smokers, and they benefited from a positive modification of the efficacy of clopidogrel.

AB - Background: The “smoker’s paradox” is an otherwise unexplained phenomenon in which the mortality of smokers after acute myocardial infarction is reduced, contrary to expectations. It has been suggested that an association with antiplatelet agents exists, but the true mechanism remains largely unidentified. Methods and Results: The analysis included 6,195 consecutive patients who underwent percutaneous coronary intervention (PCI) for acute coronary syndrome, registered in the Japanese multicenter PCI registry. Smokers were significantly younger and had less comorbidity than non-smokers. Unadjusted in-hospital mortality rate, general complication rate, and bleeding complication rate were lower in smokers than in non-smokers. After adjustment, the trend persisted and smoking was not associated with overall mortality (odds ratio [OR], 0.90; 95% confidence interval [CI]: 0.61–1.34; P=0.62), and was associated with lower overall (P=0.032) and bleeding complication events (P=0.040). Clopidogrel effectively reduced the occurrence of in-hospital complications and major adverse cardiac events in smokers compared with non-smokers (OR, 0.55; 95% CI: 0.53–0.98 vs. OR, 1.20; 95% CI: 0.87–1.67; and OR, 0.37; 95% CI: 0.20–0.70 vs. OR, 1.48; 95% CI: 0.90–2.43, respectively). Conclusions: The smoker’s paradox was largely explained by confounding factors related to the lower risk profile of smokers, and they benefited from a positive modification of the efficacy of clopidogrel.

KW - Acute coronary syndrome

KW - Clopidogrel

KW - Percutaneous coronary intervention

KW - Smoking

KW - ST-segment elevation myocardial infarction

UR - http://www.scopus.com/inward/record.url?scp=84975722519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975722519&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-16-0032

DO - 10.1253/circj.CJ-16-0032

M3 - Article

C2 - 27245240

AN - SCOPUS:84975722519

VL - 80

SP - 1590

EP - 1599

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 7

ER -